

# Servier Pharmaceuticals



# Table of Contents

Navigate directly to the section of your choice by clicking on the page name

# Who We Are



Independent, privately held U.S. pharmaceutical company governed by a non-profit foundation



Focus on oncology treatment and care with two oncology products on the market for blood cancer



Expansion planned to other therapeutic areas via partnerships and licensing deals

---

We are a commercial stage, privately held pharmaceutical company. Launched by Servier Group, a unique global organization operating in more than 150 countries and governed by a non-profit foundation, Servier Pharmaceuticals has the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of a biotech.

Currently, oncology treatment and care are our immediate focus in the United States. We have two products on the market for acute lymphoblastic leukemia (ALL), a rare blood cancer, and plan to expand into other therapeutic areas.

**To advance research and address patient needs, we partner for a purpose: our patients. Patients are at the heart of everything we do at Servier, and we seek out partners who share our values and commitment.**

**“At Servier Pharmaceuticals, we are dedicated to bringing the promise of tomorrow to the patients we serve.”**

# What We Stand For

## Vocation

We are inspired by our **vocation**, which is our commitment to the therapeutic programs and the patients we serve.

## Vision

We are guided by our **vision**, which puts patients at the heart of our decisions. This patient focus is central to everything we are doing. We continue to make long-term and independent investments in innovation. While we are a U.S. company, we have a global impact and we strive to contribute to quality health care for all who need it.

## Values

We are driven by our **values**.



Click the arrow beneath each value to read full description

# Our Expertise

At Servier Pharmaceuticals, we are committed to making the world a better place for the patients we serve. Our research focuses on five key therapeutic areas: Oncology, Cardiology, Metabolism, Immune-inflammatory and Neuroscience. Our extensive know-how and expertise position us to best address the unmet needs of patients. Servier draws on the excellence of its R&D employees worldwide to develop effective treatment solutions.

Of note, cancer is the second cause of mortality globally, and it continues to rise. The World Health Organization estimates 22 million new cases per year over the next two decades. Given the magnitude of therapeutic needs in oncology, Servier made the fight against cancer our #1 strategic priority. Servier's oncology R&D programs explore two significant areas: cancer-cell signaling and immuno-oncology.

With multiple partnerships worldwide with leading biotech companies and academic institutions for oncology projects, Servier Pharmaceuticals is poised to pursue our ambition to be a vital force in advancing cancer innovation and provide new therapeutic solutions to patients with cancer to help improve their care.

## Areas of Interest



### Oncology

We are targeting our oncology research on two main areas: immuno-oncology and cancer-cell signaling. We are actively looking at strengthening our commercial-stage portfolio and licensing-in/acquiring commercial and late-stage products (on the market ~2021) in hemato-oncology. Prioritized indications are hematological malignancies and solid tumors, such as, gastrointestinal (colon, gastric, pancreas), breast and lung cancers.

Our current collaborations and licenses include an emphasis on targeted protein degradation, epigenetic modifications, vectorization of BH3 mimetics, immune-oncology modulators (small molecules, antibodies) and CAR-T cells related technologies.



### Cardiology

We are targeting our cardiology research on heart failure and arrhythmias in general and specific populations.

Our current collaborations and licenses include an emphasis on heart failure, atrial fibrillation, systemic hypertension, coronary artery diseases, arrhythmic cardiomyopathies, hyperlipidemia and venous diseases.

# “Servier made the fight against cancer our #1 strategic priority.”



## Metabolism

We are targeting our metabolic research on the treatment of type 2 diabetes and its complications, such as non-alcoholic steatohepatitis (NASH), diabetic kidney and liver disease. Our goal is to maintain a portfolio of drug discovery projects across several critical biological pathways implicated in disease progression and reversal.

Our current collaborations and licensing deals include an emphasis on diabetic retinopathy and non-injectable insulins.



## Immune-inflammatory

We are targeting our immune-inflammatory research on lupus, primary Sjögren's syndrome and systemic sclerosis as well as other chronic inflammatory and fibrotic diseases sharing similar pathophysiological mechanisms.

Our current collaborations and licensing deals include an emphasis on autoimmune and fibrotic disorders.



## Neuroscience

We are targeting our neuroscience research on proteinopathies, characterized by abnormal accumulation of specific proteins such as Parkinson's disease, autism, Alzheimer's disease, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), Huntington's disease, and other rare diseases in neurodevelopmental and neurodegenerative disorders.

Our current collaborations and licenses include an emphasis on sub-populations and rare forms of neurodegenerative disease.

# Our Approach


**We Bring Life-Saving Treatments to Patients Through...**

## Network Partnerships

Alliances, collaboration and co-creation to bring solutions to patients and accelerate access

## Development Partnerships

Finding the best modality for the right target in the right patient at the right time



## Patient Advocacy

Dedication to supporting patients, caregivers, families and patient organizations

## Pipeline

Pursuit of new therapies that bring real value to patients and caregivers

We strategically direct our resources to partnerships and activities that further accelerate the research and development of innovative treatments. As a privately held company, Servier Pharmaceuticals has the freedom to maintain a steady focus on the most urgent needs of patients. Our independence fosters more forward-thinking and sustainable choices for the long-term.

**“Our independence fosters more forward-thinking and sustainable choices for the long-term.”**

## Patient Advocacy

Our deep commitment to patients is fundamental to our culture. We consistently engage with patients, caregivers, families and organizations to fully understand the needs of the patient communities we serve. Through ongoing partnerships with patient experts and advocacy groups, we can expand our knowledge on patient needs each day.

We have created a Patient Expert Council comprised of people living with cancer and their caregivers who provide insights and feedback that are ingrained into everything we do at Servier Pharmaceuticals. Collaborating, exchanging knowledge and building programming that supports patients and their families is critical to our program and focusing on ensuring access to care, education, unmet needs, engagement in research and building the patient community is core to our Advocacy program.

## Pipeline & Products

We are committed to building a robust portfolio of treatments starting with oncology and potentially expanding to other therapeutic areas. Globally, we are continuously reinvesting 25 percent of our revenue (excluding generics) in our research or through alliances and partnerships that drive research and development to address unmet patient needs in various therapeutic areas. Our global pipeline includes more than a dozen oncology projects at varying stages of clinical development.

## Development Partnerships

We are dedicated to finding the best modality for the right target in the right patient at the right time. We are focused on identifying R&D opportunities and expediting business development and licensing activities in the U.S. from the earliest research stages through to commercialization.

## Network & Partnerships

We believe collaboration and co-creation are fundamental to driving innovation. We are actively building the kinds of alliances that bring solutions to patients' lives and accelerate access to therapies. We seek to partner and engage with a variety of stakeholders, including world-class academic researchers, technology transfer and development offices, non-profit foundations and patient advocacy organizations, company builders, venture capitalists, strategic biotechnology and pharma partners.



# Survivorship

Survivorship is not an outcome; it's a state of being. We strive to cultivate a more well-rounded approach to cancer care, from diagnosis, treatment, and beyond remission with medicine, tools and resources that meet the long-term needs of the patients we serve.

We champion survivorship by collaborating on programs that ensure that patients have the resources and support they need. While we are focused on saving lives, we also consider the long-term impacts of treatments and illnesses on quality of life. Our commitment to survivorship is the foundation of our belief in being a responsible corporate citizen – not just for the patients who are surviving disease, but also for their families and communities.

## Issues that Matter to Us



We are proud to stand up for **critical issues and the world we serve**. One of the main issues we stand for is access and quality medical care for all. We have confidence in the American drug safety systems and respect for foreign drug supply. We are committed to providing affordable pricing and reduced pricing for eligible healthcare. We support innovation for new biologics, as well as biosimilar competition, to enhance access and reduce costs for patients.



We are proud to stand up and speak out for **social justice and equality**. We are committed to creating and supporting safe and fair environments where social justice, equality and human rights can thrive. Our company is proud to foster a culture of diversity and inclusion internally and throughout the Servier community.



We are committed to **open transparent innovation and responsible practices**. We believe in accelerating the development of new treatments for pediatric and adult patients. We are acutely focused on advancing innovation.

To learn more, go to [www.servier.us](http://www.servier.us)